Michael Hallek, MD

Faculty of Medicine and University Hospital Cologne
Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne, Germany

N/A

Poster(s):

• 1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL

• 1045 - LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1

• 1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages

• 1212 - Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry

• 2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study